3-(6-methoxynaphthalen-2-yl)acrylic acid | 3453-39-2

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: 3-(6-methoxynaphthalen-2-yl)acrylic acid
• 英文别名: β-<6-Methoxy-2-naphthyl>-acrylsaeure；β-(6-Methoxy-2-naphthyl)-acrylsaeure；3-(6-methoxynaphthalen-2-yl)prop-2-enoic acid
• CAS: 3453-39-2
• 化学式: C₁₄H₁₂O₃
• 分子量: 228.247
• InChiKey: XWGUEUJOVZAMMF-UHFFFAOYSA-N

物化性质

• 沸点：
  427.7±20.0 °C(Predicted)
• 密度：
  1.246±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(6-methoxynaphthalen-2-yl)acrylic acid 在 4-二甲氨基吡啶 、 草酰氯 、 三乙胺 作用下， 以 乙醚 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 5.0h， 生成 {3-[3'-(6''-methoxynaphthalen-2'-yl)acrylamido]olean-12-en-28-yl}{4-[3'-(6''-methoxynaphthalen-2'-yl)acrylamido]piperazin-1-yl}methanone
  参考文献：
  名称：

  基于齐墩果酸并入肉桂酰胺的新型α-葡萄糖苷酶抑制剂的合成。

  摘要：

  设计并合成了一系列具有齐墩果酸核心和不同肉桂酸酰胺配体的α-葡萄糖苷酶抑制剂。分析了它们的初步构效关系。通常，具有3，28-二取代齐墩果酸的化合物表现出比那些28-单取代类似物更强的活性，并且肉桂酰胺取代的变化显着影响α-葡糖苷酶的抑制活性。大多数化合物显示出对α-葡萄糖苷酶的有效抑制活性，其功效比典型的α-葡萄糖苷酶抑制剂阿卡波糖强得多。

  DOI：

  10.1248/cpb.59.1051
• 作为产物：
  描述：

  6-甲氧基-2-萘甲醛 在 水 、 sodium hydride 、 sodium hydroxide 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 生成 3-(6-methoxynaphthalen-2-yl)acrylic acid
  参考文献：
  名称：

  Evaluation of synthetic naphthalene derivatives as novel chemical chaperones that mimic 4-phenylbutyric acid

  摘要：

  The chemical chaperone 4-phenylbutyric acid (4-PBA) has potential as an agent for the treatment of neurodegenerative diseases. However, the requirement of high concentrations warrants chemical optimization for clinical use. In this study, novel naphthalene derivatives with a greater chemical chaperone activity than 4-PBA were synthesized with analogy to the benzene ring. All novel compounds showed chemical chaperone activity, and 2 and 5 possessed high activity. In subsequent experiments, the protective effects of the compounds were examined in Parkinson's disease model cells, and low toxicity of 9 and 11 was related to amphiphilic substitution with naphthalene. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.12.080

文献信息

• Traceless directing group mediated branched selective alkenylation of unbiased arenes
  作者：Soumitra Agasti、Aniruddha Dey、Debabrata Maiti

  DOI：10.1039/c6cc07032a

  日期：——

  –COOH group assisted branched selective olefination of simple arenes.

  –COOH基团辅助简单芳烃的分支选择性烯基化。

• Substituted azole derivatives, compositions, and methods of use
  申请人：Mjalli M.M. Adnan

  公开号：US20050187277A1

  公开（公告）日：2005-08-25

  The present invention provides azole derivatives of Formula (I), methods of their preparation, pharmaceutical compositions comprising the compounds of Formula (I), and their use in treating human or animal disorders. The compounds of the invention can be useful as inhibitors of protein tyrosine phosphatases and thus can be useful for the management, treatment, control, or the adjunct treatment of diseases mediated by PTPase activity. Such diseases include Type I diabetes and Type II diabetes.

  本发明提供了式（I）的唑类衍生物，其制备方法，包含式（I）化合物的药物组合物，以及它们在治疗人类或动物疾病中的用途。本发明的化合物可用作蛋白酪氨酸磷酸酶的抑制剂，因此可用于管理、治疗、控制或辅助治疗由PTPase活性介导的疾病。这些疾病包括I型糖尿病和II型糖尿病。
• Substituted azole derivatives as therapeutic agents
  申请人：——

  公开号：US20040192743A1

  公开（公告）日：2004-09-30

  This invention provides azoles which may be useful as inhibitors of protein tyrosine phosphatases (PTPases). The present invention provides compounds of Formula (I), methods of their preparation, pharmaceutical compositions comprising the compounds and their use in treating human or animal disorders. The compounds of the invention may be useful as inhibitors of protein tyrosine phosphatases and thus can be useful for the management, treatment, control and adjunct treatment of diseases mediated by PTPase activity. Such diseases include Type I diabetes, Type II diabetes.

  这项发明提供了一些可能作为蛋白酪氨酸磷酸酶（PTPases）抑制剂有用的唑类化合物。本发明提供了式（I）的化合物，它们的制备方法，包含这些化合物的制药组合物以及它们在治疗人类或动物疾病中的应用。本发明的化合物可能作为蛋白酪氨酸磷酸酶的抑制剂有用，因此可用于管理、治疗、控制和辅助治疗由PTPase活性介导的疾病，如1型糖尿病、2型糖尿病等。
• Substituted Azole Derivatives as Therapeutic Agents
  申请人：Mjalli Adnan M. M.

  公开号：US20110077399A1

  公开（公告）日：2011-03-31

  This invention provides azoles which may be useful as inhibitors of protein tyrosine phosphatases (PTPases). The present invention provides compounds of Formula (I), methods of their preparation, pharmaceutical compositions comprising the compounds and their use in treating human or animal disorders. The compounds of the invention may be useful as inhibitors of protein tyrosine phosphatases and thus can be useful for the management, treatment, control and adjunct treatment of diseases mediated by PTPase activity. Such diseases include Type I diabetes, Type II diabetes.

  本发明提供了一些可能用作蛋白酪氨酸磷酸酶（PTPases）抑制剂的唑类化合物。本发明提供了式（I）的化合物，它们的制备方法，包含这些化合物的药物组合物以及它们在治疗人类或动物疾病方面的用途。本发明的化合物可能有用作蛋白酪氨酸磷酸酶的抑制剂，因此可以用于管理、治疗、控制和辅助治疗由PTPase活性介导的疾病，例如1型糖尿病、2型糖尿病。
• Substituted Azole Derivatives, Compositions, and Methods of Use
  申请人：Mjalli Adnan M.M.

  公开号：US20110092553A1

  公开（公告）日：2011-04-21

  The present invention provides azole derivatives of Formula (I), methods of their preparation, pharmaceutical compositions comprising the compounds of Formula (I), and their use in treating human or animal disorders. The compounds of the invention can be useful as inhibitors of protein tyrosine phosphatases and thus can be useful for the management, treatment, control, or the adjunct treatment of diseases mediated by PTPase activity. Such diseases include Type I diabetes and Type II diabetes.

  本发明提供式（I）的唑类衍生物，其制备方法，含有式（I）化合物的制药组合物，以及它们在治疗人类或动物疾病方面的用途。本发明的化合物可用作蛋白酪氨酸磷酸酶的抑制剂，因此可用于治疗PTPase活性介导的疾病的管理、治疗、控制或辅助治疗。这些疾病包括1型糖尿病和2型糖尿病。